Pfizer (NYSE:PFE) Stock Price Up 0.7%

Pfizer Inc. (NYSE:PFE)’s stock price rose 0.7% during trading on Wednesday . The company traded as high as $29.08 and last traded at $29.02. Approximately 4,160,349 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 38,520,637 shares. The stock had previously closed at $28.82.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Down 0.4 %

The company has a market capitalization of $162.69 billion, a PE ratio of -483.67, a P/E/G ratio of 0.98 and a beta of 0.69. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a 50 day simple moving average of $28.89 and a two-hundred day simple moving average of $27.98.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.85%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PFE. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in Pfizer in the fourth quarter valued at $2,601,000. Silver Oak Securities Incorporated raised its position in Pfizer by 51.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 13,368 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 4,522 shares during the last quarter. Gilbert & Cook Inc. lifted its holdings in shares of Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares in the last quarter. McAdam LLC grew its position in shares of Pfizer by 7.6% in the fourth quarter. McAdam LLC now owns 15,019 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 1,063 shares during the last quarter. Finally, Choreo LLC increased its stake in shares of Pfizer by 11.3% during the 4th quarter. Choreo LLC now owns 119,573 shares of the biopharmaceutical company’s stock worth $3,443,000 after purchasing an additional 12,181 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.